RedHill is at the forefront of pandemic preparedness and medical countermeasures efforts, developing two novel, potentially broad-acting, host-directed, late-stage, oral, small molecule therapies, with intrinsic viral mutation-resistant properties, suitable for stockpiling and easy distribution and administration as a medical countermeasure in the event of biological, chemical, viral or radiological exposure due to pandemics & disease outbreaks, accidents, warfare or terrorism.

Learn more about our development programs: